Clinical trial NCT02795117: Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Rosacea
Lead sponsor: Padagis LLC
Sponsor class: INDUSTRY
First posted: 2016-06-09
Enrollment: 486
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of inflammatory lesions rosacea


Eligibility criteria: Inclusion Criteria:

1. Must sign an Institutional Review Board (IRB) approved written informed consent for this study.
2. Must be at least 18 years of age
3. Must have a definite clinical diagnosis of moderate to severe facial papulopustular rosacea
4. Subjects must be willing and able to understand and comply with the requirements of the study and apply the medication as instructed.
5. Subjects must be in general good health and free from any clinically significant disease, other than rosacea, that might interfere with the study evaluations.
6. Females of childbearing potential (excluding women who are surgically sterilized (verified tubal ligation or bilateral oophorectomy or hysterectomy) or post- menopausal for at least 2 years), in addition to having a negative urine pregnancy test at Visit 1/Day 1 (Baseline), must be willing to use an acceptable form of birth control during the study.

Exclusion Criteria:

1. Subjects, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation.
2. Current or past ocular rosacea.
3. Presence of any other facial skin condition that might interfere with rosacea diagnosis and/or assessment.
4. History of hypersensitivity or allergy to the study medication and/or any ingredient in the study medication.
5. Use of radiation therapy and/or anti-neoplastic agents within 90 days prior to Visit 1/Day 1 (Baseline).
6. Current use of anticoagulation therapy and use throughout the study.
7. Use of medicated make-up (including anti-aging make-up) throughout the study
8. Use during the study of 1) systemic steroids, 2) topical retinoids to the face 3) antibiotics known to impact rosacea 4) immunosuppressive agents, or immunomodulators).
9. Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics.
10. Use of medicated cleansers on the face (throughout the study.
11. Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements
12. Use of topical astringents or abrasives, medicated topical preparations (prescription and OTC products) within 2 days prior to Visit 1 and throughout the study.
13. Use of antipruritics (including antihistamines), spa treatments or chlorine exposure (swimming etc.) within 24 hours of all study visits.
14. Participation in any clinical study involving an investigational product, agent or device that might influence the intended effects or mask the side effects of study medication in the 1 month (30 days) prior Visit 1/Day 1 (Baseline) or throughout the study.
15. Previous enrollment in this study or current enrollment in this study at another participating site.
16. Use of tanning booths, sun lamps (excessive UV radiation e.g., phototherapy, daily extended exposure or occupational exposure to the sun), sunbathing or excessive exposure to the sun 1 week prior to baseline and throughout the study.
17. Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study

Primary outcomes:
measure: Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count
timeFrame: Day 1 to Day 84
Secondary outcomes:
measure: Subjects With Clinical Success on the Investigator Global Assessment
timeFrame: Day 1 to Day 84
Other outcomes:
Locations:
Study officials:
References: